As referred in Supplementary Table 1, both 40 variants were suggested to be RGS1 and RASGRP1 variants impacting susceptibility to immune related diseases, metabolic diseases, psychiatric diseases, and cancer. This evidence concerns the gene RASGRP1 and metabolic disease.